JAK2 INHIBITORAND NSAIDs combinated use as a treatment proposal for COVID-19: A literature review

Abstract

The search for drugs protocols to the COVID-19 treatment had been severely studied, considering the inflammation states and the thrombotic events. Objective: Propose, through a literature review, the combined use of baricitinib and apirin for patients with moderate to severe COVID-19 disease. .METHODS: An integrative literature review was carried out on Google Search and Pub Med, analyzing observational and clinical intervention studies Results: The average mortality between the studies with the aspirin was 13.25%, it was observed a lower necessity for mechanical ventilation and rate of admission to the ICU. While the baricitinb studies had an average of 6.25%, decrease in plasma concentrations of IL-6, CRP and neutrophils and an increase in the number of lymphocytes. Conclusion: The association of these two drugs shows antiviral, anti-inflammatory and antithrombotic activity, acting on JAK2 and NF-kb simultaneously.